Anavex Life Sciences (AVXL) 24th Annual Needham Virtual Healthcare Conference summary

Strategic focus and market overview

• Targeting Alzheimer's disease and dementia, with a projected patient population exceeding 150 million by 2050 and $20 trillion in cumulative care costs.

• Utilizing a precision medicine platform with novel oral small molecules, aiming for transformative impact in large, unmet medical need markets.

• Lead compound blarcamesine is in regulatory submission with the EMA, with plans to expand submissions globally.

• Operations are fully funded for at least four years with no debt, supported by disciplined cash management and non-dilutive funding.

• Patent protection for product candidates extends to 2039, covering composition of matter and methods of use.

Product pipeline and clinical development

• Blarcamesine offers a once-daily oral alternative to current injectable Alzheimer's treatments, providing patient-friendly administration and broad patent protection.

• Anavex 3-71 is in Phase 2 for schizophrenia, with top-line data expected mid-year; additional formulations target rare diseases.

• Pipeline includes other candidates (Anavex 1-41, Anavex 1066) in earlier stages, and ongoing studies in Parkinson's, Fragile X, and an undisclosed rare disease.

• Compassionate use and open-label extension programs for blarcamesine have been ongoing for over nine years.

• Preclinical data suggest potential for prophylactic use of blarcamesine in Alzheimer's.

Mechanism of action and clinical results

• Blarcamesine activates the Sigma-1 protein, restoring homeostasis and countering neurodegenerative pathology upstream of amyloid and tau.

• Demonstrated broad reduction in brain atrophy and cognitive decline in placebo-controlled and open-label studies, with earlier treatment yielding greater benefit.

• Safety profile consistent over four years, with manageable adverse events and no drug-related deaths.

• Data indicate a disease-modifying effect, with clinically meaningful improvements in cognition and daily function.

• Continuous treatment is important for sustained benefit, as interruptions led to worse outcomes.